Fig. 2From: Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine gliomaCell viability assay valuation of the predicted drugs. Triptolide (A), triamterene (B) and mycophenolate mofetil (C) in DIPG cell lines (SF8628, SU-DIPG-IV) as well as control NHA cells. Left: Graphs showing the proliferation response of normal human astrocytes (NHA) and DIPG cell lines (SU-DIPG-IV, SF8628), to increasing concentrations of each drug. Values shown are the average [mean ± standard deviation (SD)] from triplicate samples for each incubation condition. Right: Dot plot representation of IC50 values shown are the average (mean ± SD) from triplicate samples for each cell lines. Statistical analysis was performed using a two-tailed unpaired t-test: triptolide, NHA versus SU-DIPG-IV, *P < 0.05; NHA versus SF8628, *P = 0.05; triamterene, NHA versus SU-DIPG-IV, *P < 0.05; NHA versus SF8628, *P < 0.05; MMF, NHA versus SU-DIPG-IV, ***P < 0.001; NHA versus SF8628, **P < 0.01Back to article page